^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Fucaso (equecabtagene autoleucel)

    i
    Other names: CT-103A, IBI-326, CT103A, IBI326, Eque-cel, IBI 326, CT 103A
    Company:
    IASO BIO, Innovent Biologics
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    7ms
    CARTinNS: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System (clinicaltrials.gov)
    P1, N=36, Recruiting, Tongji Hospital | N=18 --> 36 | Trial completion date: May 2024 --> May 2027 | Trial primary completion date: Feb 2024 --> Feb 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • fludarabine IV • Fucaso (equecabtagene autoleucel)
    7ms
    A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. (clinicaltrials.gov)
    P=N/A, N=260, Not yet recruiting, Peking University People's Hospital
    New trial • Real-world evidence • Real-world
    |
    Fucaso (equecabtagene autoleucel)
    1year
    Long-Term Follow-up of Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma (ASH 2023)
    Lymphodepletion was performed using Fludarabine (30 mg/m2) and cyclophosphamide (500 mg/m2) for three consecutive days. The updated data from the long-term follow-up of CT103A demonstrated a durable clinical benefit for RRMM patients, based on the sustained existence of fully human CAR-T cells. In addition, the favorable safety profile strengthens the prospect of clinical application of CT103A.
    Clinical
    |
    cyclophosphamide • fludarabine IV • Fucaso (equecabtagene autoleucel)
    1year
    Equecabtagene Autoleucel: First Approval. (PubMed, Mol Diagn Ther)
    Equecabtagene autoleucel was granted conditional approval in China in June 2023 for the treatment of adults with relapsed or refractory MM (RRMM) who have progressed after ≥ 3 lines of therapy (≥ 1 proteasome inhibitor and an immunomodulator). This article summarizes the milestones in the development of equecabtagene autoleucel leading to this first approval in patients with RRMM who have progressed after multiple lines of therapy.
    Review • Journal
    |
    Fucaso (equecabtagene autoleucel)
    over1year
    CT103A, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF PHASE 1B/2 STUDY (FUMANBA-1) (EHA 2023)
    At a longer median follow-up of 13.8 months, CT103A achieved deep and long-lasting responses in heavily pre-treated patients with MM. Furthermore, patients with prior BCMA CAR-T cell therapy who achieved sCR had sustained sCR over 18 months. CT103A demonstrated a favorable safety profile with no new risk observed with longer follow-up.
    Clinical • P1/2 data • CAR T-Cell Therapy
    |
    Fucaso (equecabtagene autoleucel)
    over2years
    A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Recruiting, Chunrui Li | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IL6 (Interleukin 6)
    |
    Xpovio (selinexor) • Fucaso (equecabtagene autoleucel)
    almost3years
    A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Huazhong University of Science and Technology
    Clinical • New P1 trial
    |
    IL6 (Interleukin 6)
    |
    Xpovio (selinexor) • Fucaso (equecabtagene autoleucel)
    almost3years
    A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Nanjing IASO Biotherapeutics Co.,Ltd
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6)
    |
    Fucaso (equecabtagene autoleucel)